[en] The seriousness of varicella-zoster virus (VZV) infection as a public health issue is becoming clearer as country-specific epidemiologic and pharmacoeconomic data become available. In Germany, for example, studies have shown that >5.5% of immunologically healthy individuals develop varicella-related complications such as bacterial superinfections, acute neurologic disorders, pneumonia, bronchitis and otitis media; whereas in Italy, 3.5 to 5% of childhood cases of varicella cause complications such as upper respiratory tract and cutaneous infections. Varicella vaccines are now available. These live attenuated Oka strain vaccines have been shown in extensive studies to be highly immunogenic and well-tolerated in immunocompetent and immunocompromised children, with seroconversion rates ranging from 94 to 100% and 53 to 100%, respectively. These vaccines are also highly effective against clinical disease. These considerations led to a reevaluation of varicella vaccination policies. A routine varicella vaccination program targeting healthy children has already been implemented in the US, and data produced are encouraging and valuable. Similar strategies have not yet been adopted across Europe. The European Working Group on Varicella (EuroVar) was formed in 1998 to address the issues surrounding varicella epidemiology in Europe. After a series of meetings, the EuroVar members prepared a consensus statement recommending routine varicella vaccination for all healthy children between 12 and 18 months and to all susceptible children before their 13th birthday, in addition to catch-up vaccination in older children and adults who have no reliable history of varicella and who are at high risk of transmission and exposure. However, such a policy is recommended only if a very high coverage rate can be achieved. This could be reached with a measles-mumps-rabella-varicella combined vaccine.
Disciplines :
Pediatrics Immunology & infectious disease
Author, co-author :
Rentier, Bernard ; Université de Liège - ULiège > Département des sciences de la vie > Virologie - Immunologie
Gershon, Anne A.; Columbia Presbyterian University College of Physicians and Surgeons > Départment of Pediatrics - Infectious Diseases
Language :
English
Title :
Consensus : Varicella vaccination of healthy children - A challenge for Europe
Publication date :
2004
Journal title :
Pediatric Infectious Disease Journal
ISSN :
0891-3668
eISSN :
1532-0987
Publisher :
Lippincott Williams & Wilkins, Philadelphia, United States - Pennsylvania
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Jackson MA, Burry VF, Olson LC. Complications of varicella requiring hospitalization in previously healthy children. Pediatr Infect Dis J. 1992;11:441-445.
Miller E, Marshall R, Vurdien J. Epidemiology, outcome and control of varicella-zoster infection. Rev Med Microbiol. 1993;4:222-230.
Arvin A, Gershon A. Live attenuated varicella vaccine. Annu Rev Microbiol. 1996;50:59-100.
Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1996;45(RR-11):1-25.
Centers for Disease Control and Prevention. Prevention of varicella: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1999;48(RR-6):1-5.
Aebi C, Fischer K, Gorgievski M, Matter L, Muhlemann K. Age-specific seroprevalence to varicella-zoster virus: study in Swiss children and analysis of European data. Vaccine. 2001;19:3097-3103.
IMS Verschreibungsindex für Pharmazeutika (VIP). Frankfurt, Germany: IMS Health; 2000.
Wutzler P, Farber I, Wagenpfeil S, Bisanz H, Tischer A. Seroprevalence of varicella-zoster virus in the German population. Vaccine. 2001;20:121-124.
Ziebold C, von Kries R, Lang R, Weigl J, Schmitt HJ. Severe complications of varicella in previously healthy children in Germany: a 1-year survey. Pediatrics. 2001;108:e79.
Wutzler P, Neiss A, Banz K, Goertz A, Bisanz H. Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in Germany. Med Microbiol Immunol Berl. 2002;191:89-96.
Floret, D, Levrat, V. Severe complications of varicella: a survey in French pediatric intensive care units. In: 21st Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID). Taormina, Sicily, Italy, April 9-11, 2003.
Rawson H, Crampin A, Noah N. Deaths from chickenpox in England and Wales 1995-7: analysis of routine mortality data. BMJ. 2001;323:1091-1093.
Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine. 2001;19:3076-3090.
Bramley JC, Jones IG. Epidemiology of chickenpox in Scotland: 1981 to 1998. Commun Dis Public Health. 2000;3:282-287.
Deguen S, Chan NP, Flahault A. Epidemiology of chickenpox in France (1991-1995). J Epidemiol Community Health. 1998;52(suppl 1):46S-49S.
Salmaso S, Bella A, Ciofi degli Atti ML. SIMInews no. 3. Boll Sist Informatizzato Mal Infet. Notiziario dell'Ist Superiore Sanità. 2000; 13(10S):1-8.
Instituto Superiore di Sanità Laboratorio di Epidemiologica e Biostatistica. Sorregliaza Pediatri Sentinella. Available at: www.spes.iss.it/risu2000.htm. Accessed September 2002.
Fornaro P, Gandini F, Marin M, et al. Epidemiology and cost analysis of varicella in Italy: results of a sentinel study in the pediatric practice. Pediatr Infect Dis J. 1999;18:414-419.
Gabutti G, Penna C, Rossi M, et al. Serological Study Group. The seroepidemiology of varicella in Italy. Epidemiol Infect. 2001;126:433-440.
Salleras L, Dominguez A, Vidal J, Plans P, Salleras M, Taberner J. Seroepidemiology of varicella-zoster virus infection in Catalonia (Spain): Rationale for universal vaccination programmes. Vaccine. 2001;19:183-188.
Gil A, Oyaguez I, Carrasco P, Gonzalez A. Epidemiology of primary varicella hospitalizations in Spain. Vaccine. 2002;20:295-298.
Finger R, Hughes JP, Meade BJ, Pelletier AR, Clarkson TP. Age-specific incidence of chickenpox. Public Health Rep. 1994;109:750-755.
Jones SE, Armstrong CB, Bland C, Walter EB, Clements DA. Varicella prevalence in day-care centers. Pediatr Infect Dis J. 1995;14:404-405.
Seward JF. Update on varicella. Pediatr Infect Dis J. 2001;20:619-621.
Yawn BP, Yawn RA, Lydick E. Community impact of childhood varicella infections. J Pediatr. 1997;130:759-765.
Kudesia G, Partridge S, Farrington CP, Soltanpoor N. Changes in age related seroprevalence of antibody to varicella zoster virus: impact on vaccine strategy. J Clin Pathol. 2002;55:154-155.
Ross AM, Fleming DM. Chickenpox increasingly affects preschool children. Commun Dis Public Health. 2000;3:213-215.
Socan M, Kraigher A, Pahor L. Epidemiology of varicella in Slovenia over a 20-year period (1979-98). Epidemiol Infect. 2001;126:279-283.
Lee T, Nang RN. The epidemiology of varicella hospitalizations in the US Army. Mil Med. 2000;165:791-795.
White CJ. Clinical trials of varicella vaccine in healthy children. Infect Dis Clin North Am. 1996;10:595-608.
American Academy of Pediatrics, Committee on Infectious Diseases. Recommendations for the use of live attenuated varicella vaccine. Pediatrics. 1995;95:791-796.
American Academy of Pediatrics, Committee on Infectious Diseases. Varicella vaccine update. Pediatrics. 2000;105:136-141.
Centers for Disease Control and Prevention. National, state and urban area vaccination coverage levels among children aged 19-35 months: United States, 2000. MMWR. 2001;50:637-641.
Weibel RE, Neff BJ, Kuter BJ, et al. Live attenuated varicella virus vaccine: efficacy trial in healthy children. N Engl J Med. 1984;310:1409-1415.
Meurice G, De Bouver JL, Vandevoorde D, Woods S, Bogaerts H. Immunogenicity and safety of live attenuated varicella vaccine (Oka/SB Bio) in healthy children. J Infect Dis. 1996;174(suppl 3): S324-S329.
Ngai AL, Staehle BO, Kuter BJ, et al. Safety and immunogenicity of one vs two injections of Oka/Merck varicella vaccine in healthy children. Pediatr Infect Dis J. 1996;15:49-54.
Tan AYS, Connett CJ, Connett GJ, et al. Use of a reformulated Oka strain varicella vaccine (SmithKline Beecham Biologicals/Oka) in healthy children. Eur J Pediatr. 1996;155:706-711.
Varis T, Vesikari T. Efficacy of high-titer live attenuated varicella vaccine in healthy young children. J Infect Dis. 1996;174(suppl 3): S330-S334.
Kanra G, Ceyhan M, Ozmert E. Safety and immunogenicity of live attenuated varicella vaccine in 9-month-old children. Pediatr Int. 2000;42:674-677.
Gershon AA, Steinberg SP, the Varicella Vaccine Collaborative Study Group of the National Institute of Allergy and Infectious Diseases. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine. N Engl J Med. 1989;320:892-897.
Webb NJA, Fitzpatrick MM, Hughes DA, et al. Immunisation agaist varicella in end stage and pre-end stage renal failure, on behalf of the Trans-Pennine Paediatric Nephrology Study Group. Arch Dis Child. 2000;82:141-143.
Levin MJ, Gershon AA, Weinberg A, et al. Immunization of HIV-infected children with varicella vaccine. J Pediatr. 2001;139:305-310.
Nithichaiyo C, Chongsrisawat V, Hutagalung Y, Bock HL, Poovorawa Y. Immunogenicity and adverse effects of live attenuated varicella vaccine (Oka-strain) in children with chronic liver disease. Asian Pac J Allergy Immunol. 2001;19:101-105.
Gershon A, Steinberg S, LaRussa P. Detection of antibodies to varicella-zoster virus by latex agglutination. Clin Diag Virol. 1994;2:271-277.
Williams V, Gershon A, Brunell P. Serologic response to varicellazoster membrane antigens measured by indirect immunofluorescence. J Infect Dis. 1974;130:669.
Saiman L, LaRussa P, Steinberg SP, et al. Persistence of immunity to varicella-zoster virus after vaccination of healthcare workers. Infect Control Hosp Epidemiol. 2001;22:279-283.
Vessey SJ, Chan CY, Kuter BJ, et al. Childhood vaccination against varicella: persistence of antibody, duration of protection, and vaccine efficacy. J Pediatr. 2001;139:297-304.
Vazquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med. 2001;344:955-960.
Clements DA, Armstrong CB, Ursano AM, et al. Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents. Pediatr Infect Dis J. 1995;14:874-879.
LaRussa P, Steinberg SP, Shapiro E, Vazquez M, Gershon AA. Viral strain identification in varicella vaccinees with disseminated rashes. Pediatr Infect Dis J. 2000;19:1037-1039.
Watson BM, Piercy SA, Plotikin SA, Starr SE. Modified chickenpox in children immunized with the Oka/Merck varicella vaccine. Pediatrics. 1993;91:17-22.
Takayama N, Minamitani M, Takayama M. High incidence of break-through varicella observed in healthy Japanese children immunized with live attenuated varicella vaccine (Oka strain). Acta Paediatr Jpn. 1997;39:663-668.
Burnham BR, Wells TS, Riddle JR. A cost-benefit analysis of a routine varicella vaccination program for United States Air Force Academy Cadets. Mil Med. 1998;163:631-634.
Gershon AA. Varicella vaccine: are two doses better than one? N Engl J Med. 2002;347:1909-1915.
Johnson CE, Stancin T, Fattlar D, Rome LP, Kumar ML. A long-term prospective study of varicella vaccine in healthy children. Pediatrics. 1997;100:761-766.
Kuter BJ, Weibel RE, Guess HA, et al. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine. 1991;9:643-647.
Black S, Shinefield H, Ray P, et al. Postmarketing evaluation of the safety and effectiveness of varicella vaccine. Pediatr Infect Dis J. 1999;18:1041-1046.
Diaz-Mitoma F, Halperin SA, Scheifele D. Reactogenicity to a live attenuated varicella vaccine in Canadian children. Can J Infect Dis. 2000;11:97-102.
Sharrar RG, LaRussa P, Galea SA, et al. The postmarketing safety profile of varicella vaccine. Vaccine. 2001;19:916-923.
Liang MG, Heidelberg KA, Jacobson RM, McEvoy MT. Herpes zoster after varicella immunization. J Am Acad Dermatol. 1998;38:761-763.
Gershon AA. Live attenuated varicella vaccine. Int J Infect Dis. 1997;1:130-134.
Hardy I, Gershon AA, Steinberg S, Larussa P. The incidence of zoster after immunization with live attenuated varicella vaccine. N Engl J Med. 1991;325:1545-1550.
Lawrence R, Gershon AA, Holdzman R, Steinberg S. The risk of zoster after varicella vaccination in children with leukemia. N Engl J Med. 1988;318:543-548.
Brunell PA, Taylor-Wiedeman J, Geiser CF, Grierson L, Lydick E. Risk of herpes zoster in children with leukemia: varicella vaccine compared with history of chickenpox. Pediatrics. 1986;77:53-57.
White CJ. Letter to editor. Pediatrics. 1992;89:354.
Holmes SJ. Prevention of varicella (1996). MMWR. 1996;45(RR-11): 1-36.
Halloran ME, Cochi SL, Lieu TA, Wharton M, Fehrs L. Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am J Epidemiol. 1994;140:81-104.
Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G. Modelling the impact of immunization on the epidemiology of varicella-zoster virus. Epidemiol Infect. 2000;125:651-659.
Seward JF. Update on varicella and varicella vaccine, United States. In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, December 16-19, 2001. Washington, DC: American Society for Microbiology; 2001.
Seward JF, Watson BM, Peterson CL. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA. 2002;287:606-611.
Jumaan AOA, Yu O, Bohlke K, Jackson L, Galil K, Seward J. Varicella and herpes zoster incidence before and after varicella vaccine licensure, 1992-2001. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 14-17, 2003. Washington, DC: American Society for Microbiology; 2003:286
Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine. 2002;20:19-20.
Seward JF, Jumaan AO, Galil K, Wharton M. Varicella vaccine and shingles [letter]. JAMA. 2002;287:2211-2212.
Zerboni L, Nader S, Aoki K, Arvin AM. Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine. J Infect Dis. 1998;177:1701-1704.
Ampofo K, Saiman L, LaRussa P, Steinberg S, Annunziato P, Gershon A. Persistence of immunity to live attenuated varicella vaccine in healthy adults. Clin Infect Dis. 2002;34:774-779.
Asano Y, Suga A, Yoshikawa T, et al. Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics. 1994;94:524-526.
Shields KE, Galil K, Seward J, Sharrar RG, Cordero JF, Slater E. Varicella vaccine exposure during pregnancy: data from the first 5 years of the pregnancy registry. Obstet Gynecol. 2001;98:14-19.
Enders G, Miller E, Cradock-Watson J, Bolley I, Ridehalgh M. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet. 1994;343:1548-1551.
Paryani SG, Arvin AM. Intrauterine infection with varicella-zoster virus after maternal varicella. N Engl J Med. 1986;314:1542-1546.
Sauerbrei A, Wutzler P. Neonatal varicella. J Perinatol. 2001;21:545-549.
Gershon A. Chickenpox, measles, and mumps. In: Remington J, Klein J, eds. Infections of the Fetus and Newborn Infant. Vol 5. 3rd ed. Philadelphia, PA: Saunders; 2001.
Feldman S, Lott L. Varicella in children with cancer: impact of antiviral therapy and prophylaxis. Pediatrics. 1987;80:465-472.
Faoagali JL, Darcy D. Chickenpox outbreak among the staff of a large, urban adult hospital: costs of monitoring and control. Am J Infect Control. 1995;23:247-250.
Gray AM, Fenn P, Weinberg J, Miller E, McGuire A. An economic analysis of varicella vaccination for healthcare workers. Epidemiol Infect. 1997;119:209-220.
Nettleman MD, Schmid M. Controlling varicella in the healthcare setting: the cost effectiveness of using varicella vaccine in healthcare workers. Infect Control Hosp Epidemiol. 1997;18:504-508.
Tennenberg AM, Brassard JE, Van Lieu J, Drusin LM. Varicella vaccination for healthcare workers at a university hospital: an analysis of costs and benefits. Infect Control Hosp Epidemiol. 1997;18:405-411.
Weber DJ, Rutala WA, Parham C. Impact and costs of varicella prevention in a university hospital. Am J Public Health. 1988;78:19-23.
Saiman L, LaRussa P, Steinberg SP, Vol 5. et al. Persistence of immunity to varicella-zoster virus after vaccination of healthcare workers. Infect Control Hosp Epidemiol. 2001;22:279-283.
Ross AH. Modification of chickenpox in family contacts by administration of γ globulin. N Engl J Med. 1962;267:369-376.
Ndumbe PM, Cradock-Watson JE, MacQueen S, et al. Immunization of nurses with a live varicella vaccine. Lancet. 1985;1:1144-1147.
Oshiro AC, Begue RE, Steele RW. Varicella disease and transmission in pediatric house officers. Pediatr Infect Dis J. 1996;15:461-462.
Saddier P, Floret D, Guess HA, et al. Costs of varicella in France: a study in day care centers. J Infect Dis. 1998;178(suppl 1):S58-S63.
Law B, Fitzsimon C, Ford-Jones L, McCormick J, Riviere M. Cost of chickenpox in Canada: part I. Cost of uncomplicated cases. Pediatrics. 1999a;104:1-6.
Law B, Fitzsimon C, Ford-Jones L, McCormick J, Riviere M. Cost of chickenpox in Canada: part II. Cost of complicated cases and total economic impact. Pediatrics. 1999b;104:7-14.
Wagenpfeil S, Neiss A, Goertz A, Bisanz H, Wutzler P. Varicella epidemiology in Germany for health economic analyses. In: The Fourth International Conference on Varicella, Herpes Zoster, Post-herpetic Neuralgia (PHN), La Jolla, CA, March 3-5, 2001.
Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA. 1994;271:375-381.
Beutels P, Clara R, Tormans G, Van Doorslaer E, Van Damme P. Costs and benefits of routine varicella vaccination in German children. J Infect Dis. 1996;174(suppl 3):S335-S341.
Coudeville L, Paree F, Lebrun T, Sailly JC. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine. 1999;17:142-151.
Diez Domingo J, Ridao M, Latour J, Ballester A, Morant A. A cost-benefit analysis of routine varicella vaccination in Spain. Vaccine. 1999;17:1306-1311.
Scuffham P, Devlin N, Eberhart-Phillips J, Wilson-Salt R. The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunization schedule. Soc Sci Med. 1999;49:763-779.
Scuffham PA, Lowin AV, Burgess MA. The cost-effectiveness of varicella vaccination programs for Australia. Vaccine. 2000;18:407-415.
Streeton C, Tilden D, Davey P, Wong J, Coleman K, Burridge J. An economic evaluation of universal varicella vaccination in Australian infants [Abstract OP-F5-08]. In: 23rd International Congress of Pediatrics, 2nd International Congress on Pediatric Nursing, Beijing, China, September 9-14, 2001.
Brisson M, Edmunds WJ. The cost-effectiveness of varicella vaccination in Canada. Vaccine. 2002;20:1113-1125.
Thiry N, Beutels P, Van Damme P, Van Doorselaer. Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics. 2003;21:13-38.
Ferson MJ, Shen WL, Stark A. Direct and indirect costs of chickenpox in young children. J Paediatr Child Health. 1998;34:18-21.
Banz K, Wagenpfeil S, Neiss A, et al. The cost-effectiveness of routine childhood varicella vaccination in Germany. Vaccine. 2003;7:21:11-12.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
